Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic clocks as quantitative readouts of epigenetic drift.

Nature aging·2026
Same author

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026
Same author

Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

American journal of hematology·2026
Same author

Pretransplantation Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia Patients: A Real-World Analysis from the Cooperative Transplant Study Group.

Transplantation and cellular therapy·2025

Related Experiment Video

Updated: May 30, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Array-based DNA methylation profiling in acute myeloid leukaemia.

Stefan Wilop1, Agustín F Fernandez, Edgar Jost

  • 1Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Pauwelsstrasse 30, Aachen, Germany. swilop@ukaachen.de

British Journal of Haematology
|July 28, 2011
PubMed
Summary
This summary is machine-generated.

DNA methylation patterns are altered in acute myeloid leukemia (AML), with increased promoter hypermethylation observed at relapse. These epigenetic changes offer distinct profiles for AML subtypes and normal controls.

More Related Videos

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution
13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

Related Experiment Videos

Last Updated: May 30, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution
13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Molecular Genetics

Background:

  • Gene promoter methylation is crucial for regulating gene expression.
  • Aberrant DNA methylation is implicated in various cancers, including acute myeloid leukemia (AML).
  • Understanding methylation patterns in AML is vital for diagnostics and therapeutics.

Purpose of the Study:

  • To investigate genome-wide DNA methylation profiles in acute myeloid leukemia (AML) at diagnosis and relapse.
  • To identify specific methylation patterns associated with AML subtypes and cytogenetic aberrations.
  • To explore the role of promoter hypermethylation in AML progression and recurrence.

Main Methods:

  • Utilized the Illumina GoldenGate© methylation assay to analyze 1505 CpG sites across 807 genes in 32 diagnostic AML, 9 relapsed AML, and 15 normal control samples.
  • Performed pyrosequencing and methylation-specific polymerase chain reaction (MSP) to validate findings for the GNMT promoter in 113 diagnostic AML samples.
  • Employed cluster analysis to identify distinct epigenetic modifications associated with cytogenetic subgroups.

Main Results:

  • Demonstrated a significant gain of overall DNA methylation in AML samples compared to normal controls, with a further increase observed at relapse.
  • Confirmed regional hypermethylation in AML using array analysis, validated by MSP and pyrosequencing.
  • Identified distinct methylation profiles differentiating non-malignant controls from AML samples, including those with specific chromosomal aberrations.

Conclusions:

  • Promoter hypermethylation is a frequent epigenetic event in acute myeloid leukemia (AML) and is notably accentuated at relapse.
  • Array-based methylation analysis can distinguish AML subtypes and identify potential target genes for further investigation.
  • Epigenetic modifications in AML are linked to cytogenetic subgroups, with core DNA methylation patterns persisting at relapse.